Nxera Pharma Co., Ltd. (4565) Earnings Releases & Disclosures
| Date | Type | Title | Files |
|---|---|---|---|
| 2026-09-03 | — | Nxera Pharma to Receive $8.6 Million Milestone Payment from Centessa Pharmaceuticals Following Late-stage Development Progress | |
| 2026-08-26 | — | Nxera Pharma’s Partner Neurocrine Biosciences Receives IND Acceptance from the FDA for Phase 2 Study of NBI-1117567 for Alzheimer's Cognition | |
| 2026-08-07 | Earnings Release | Consolidated Financial Results for the Six Months Ended June 30, 2026 (IFRS) | |
| 2026-08-07 | — | Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter 2026 |
TDnet keeps only 31 days; this site accumulates daily and cannot backfill earlier disclosures.